View Printer-Friendly PDF

A Drug Development & Outsourcing Profile

Antibe Therapeutics Inc.

15 Prince Arthur Ave
Toronto ON  M5R 1B2
Canada

  • Tel: 416-473-4095
  • CEO: Mr. Daniel Legault
  • CFO: Mr. Alain Wilson
  • R&D:
  • Licng:
  • Est: 2009 - Public
  • Rev: $5–10 M
  • Staff: 10–50
  • Therapeutics-Human
  • Chronic Disease
  • Anti-inflammatory
  • Osteoarthritis
  • Pain Management
  • Dental/Oral
  • Tissue Regeneration

Antibe is a commercial-stage pharmaceutical company focused on pain, inflammation and regenerative medicine. Antibe's lead drug, ATB-346, targets the global need for a safer non-steroidal anti-inflammatory drug (“NSAID”) for treating chronic pain and inflammation with non-addictive medication. Antibe's subsidiary, Citagenix Inc., is a leader in Canada in the sales and marketing of tissue regenerative products servicing the orthopaedic and dental marketplaces, and is active internationally via distributors.

Mfg:    Labs:

ATE

0.0038